End Points The principal efficacy and safety end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal ischemic stroke. The secondary efficacy end point included the principal composite end hospitalization plus point for heart failure, coronary revascularization, or unstable angina. Definitions of the final end points, which are provided in the Supplementary Appendix, were developed to end up being consistent with the definitions in the Standardized Definitions for End Stage Events in Cardiovascular Trials draft, which was produced as an initiative of the Food and Drug Administration.20 Pancreatitis was classified as acute or chronic.Drug and Food Administration that could have resulted in the failures in some of the devices. After a death of a patient in 2004, Guidant sent out a product revise to advise doctors that the yellowish warning display screen warned of a possibly serious problem in these devices in 2005. This change made to reduce the ongoing health risk had not been reported as product correction but as product update. Guidant broke the statutory law by not notifying the FDA about the transformation within 10 days. Guidant has agreed to pay a mixed criminal penalty greater than $296 million, the U.S. Attorney’s Office for the District of Minnesota said in a statement on Monday. Within this amount a $42 million in forfeiture funds can be included and the victims could petition the Justice Department for a share.